Literature DB >> 24289075

Resveratrol attenuates left ventricular remodeling in old rats with COPD induced by cigarette smoke exposure and LPS instillation.

Yi Xin Hu1, Hua Cui, Li Fan, Xiu Jie Pan, Ji Hua Wu, Suo Zhu Shi, Shao Yuan Cui, Zhi Min Wei, Lin Liu.   

Abstract

The objective of this study was to investigate left cardiac damage and the cardioprotective effects of resveratrol in old rats with COPD. Rats 22 months old were divided into three groups: control (CTL), smoking and lipopolysaccharides (SM/LPS), and SM/LPS plus resveratrol (SM/LPS-Res). Cardiac function, pathology, oxidative stress, and apoptosis index were measured. Expression of myocardial SIRT1 was studied by real-time quantitative polymerase chain reaction (PCR) and Western blot detection. The heart weight-body weight ratio (LVW/BW) increased in the SM/LPS group compared with the CTL group. Both the LVW/BW and the area of fibrosis in the SM/LPS-Res group decreased compared with those in the SM/LPS group. 8-OHdG expression increased in cardiac tissue of rats in the SM/LPS group, which could be inhibited by resveratrol. Resveratrol significantly increased the activity of superoxide dismutase (SOD) and reduced the cardiac malonyldialdehyde (MDA) level in the SM/LPS-Res group. There was a significant decrease in the extent of cardiomyocyte apoptosis in the SM/LPS-Res group compared with the SM/LPS group. SIRT1 mRNA increased in the SM/LPS-Res group compared with the SM/LPS group. In conclusion, resveratrol attenuated cardiac oxidative damage and left ventricular remodeling and enhanced the decreased expression of SIRT1 in hearts of old rats with emphysema and thus might be a therapeutic modality for cardiac injury complicated in chronic obstructive pulmonary disease (COPD).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24289075     DOI: 10.1139/cjpp-2012-0464

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  7 in total

1.  Silent information regulator 1 (SIRT1) promotes the migration and proliferation of endothelial progenitor cells through the PI3K/Akt/eNOS signaling pathway.

Authors:  Wei Li; Dayong Du; Hang Wang; Yang Liu; Xiaohui Lai; Feng Jiang; Dong Chen; Yanbin Zhang; Jiaxin Zong; Yuntian Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart.

Authors:  Thomas K Sin; Angus P Yu; Benjamin Y Yung; Shea Ping Yip; Lawrence W Chan; Cesar S Wong; Michael Ying; John A Rudd; Parco M Siu
Journal:  J Physiol       Date:  2014-03-17       Impact factor: 5.182

3.  Cardiovascular effects in rats after intratracheal instillation of metal welding particles.

Authors:  Wen Zheng; James M Antonini; Yen-Chang Lin; Jenny R Roberts; Michael L Kashon; Vincent Castranova; Hong Kan
Journal:  Inhal Toxicol       Date:  2015-01       Impact factor: 2.724

4.  Effect of Nasal CPAP on SIRT1 and Endothelial Function in Obstructive Sleep Apnea Syndrome.

Authors:  Wei-Ji Chen; Shwu-Fang Liaw; Ching-Chi Lin; Chung-Hsin Chiu; Mei-Wei Lin; Feng-Ting Chang
Journal:  Lung       Date:  2015-09-07       Impact factor: 2.584

Review 5.  Potential Natural Small Molecular Compounds for the Treatment of Chronic Obstructive Pulmonary Disease: An Overview.

Authors:  Liu-Ying Li; Chuan-Tao Zhang; Feng-Ya Zhu; Gang Zheng; Yu-Fei Liu; Ke Liu; Chen-Hui Zhang; Hong Zhang
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

Review 6.  Role of resveratrol in inhibiting pathological cardiac remodeling.

Authors:  Shaowei Fan; Yuanhui Hu; Yaping You; Wenjing Xue; Ruoning Chai; Xuesong Zhang; Xintian Shou; Jingjing Shi
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

7.  The Effects of Resveratrol on Inflammation and Oxidative Stress in a Rat Model of Chronic Obstructive Pulmonary Disease.

Authors:  Xiao-Li Wang; Ting Li; Ji-Hong Li; Shu-Ying Miao; Xian-Zhong Xiao
Journal:  Molecules       Date:  2017-09-12       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.